Business Wire

UserTesting and Startup Grind Scotland Join Forces to Discuss Importance of Empathetic Leadership

Share

UserTesting (NYSE: USER), a leader in video-based human insight, today announced that UserTesting CEO Andy MacMillan will be joining host Nick Murray, Co-Director Startup Grind Scotland and Strategic Partnerships Manager, Metanomic, for a discussion focused on topics that include empathy in leadership, and what makes Edinburgh an ideal location as a European headquarters for technology companies. This event is taking place on Thursday, August 4, at UserTesting’s European headquarters in Edinburgh.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005085/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Nick Murray, Host and Co-Director Startup Grind Scotland and Andy MacMillan, CEO of UserTesting (Photo: Business Wire)

Attendees also can hear what Scotland can learn from Silicon Valley’s mindset, the value of customer insights in helping to drive business decisions during challenging economic periods, and lessons learned from rapidly growing a SaaS company through an IPO.

Discussion Details:

  • Date: Thursday, August 4, 2022
  • Time: 6:00 p.m. to 9:00 p.m., BST
  • Location: UserTesting EMEA Headquarters, 2nd Floor, 7 Exchange Crescent, Edinburgh, EH3 8AN
  • Cost: 6 GBP public, Free for UserTesting team members (prior registration required)
  • Speakers:
    • Andy MacMillan, CEO of UserTesting
    • Nick Murray, Host and Co-Director Startup Grind Scotland

"Community gatherings with globally-proven industry experts are critical to developing Scotland's entrepreneurial ecosystem," said Nick Murray, Co-Director of Startup Grind Scotland. "Our first interview with Andy in Silicon Valley this April was a significant mindset shift for the 20 Scottish founders we took to the entrepreneurship mecca. With the Scottish Government announcing Scotland's Tech Scaler Hubs this month, now is the perfect time to look internationally to find best practices and learn from those who have been there before. This interview will broaden the horizons of what's possible for Scottish businesses through the eyes of someone who has had incredible success in scaling a SAAS business to a global entity."

“Selecting Edinburgh was the right choice for UserTesting’s European headquarters, and we are excited to be a part of this event, highlighting the value we have found in establishing offices here,” said Andy MacMillan, CEO of UserTesting. “UserTesting is proud to support Edinburgh’s, and Scotland’s, growing technology scene. There are great opportunities for companies in Scotland, due to the local education system, partnership opportunities with local government agencies, and the local talent, which is what global technology companies are looking for today.”

About UserTesting
UserTesting (NYSE: USER) has fundamentally changed the way organizations get insights from customers with fast, opt-in feedback and experience capture technology. The UserTesting Human Insight Platform taps into our global network of real people and generates video-based recorded experiences, so anyone in an organization can directly ask questions, hear what users say, see what they mean, and understand what it’s actually like to be a customer. Unlike approaches that track user behavior then try to infer what that behavior means, UserTesting reduces guesswork and brings customer experience data to life with human insight. UserTesting has approximately 2,500 customers, including more than half of the world’s top 100 most valuable brands according to Forbes. UserTesting is headquartered in San Francisco, California. To learn more, visit www.usertesting.com.

About Startup Grind Scotland
Startup Grind is the world's largest community of startups, founders, innovators, and creators based in 125+ countries with 600 chapters worldwide. Startup Grind Scotland is committed to supporting Scotland's vibrant entrepreneurial community, hosting fireside chats and panel conversations with some of Scotland's most influential and exciting business leaders. Past speakers include Mark Logan (Scotland's Chief Entrepreneur and ex-Skyscanner COO), Darina Garland (co-founder, Ooni) and Evelyn McDonald (CEO, Scottish EDGE).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

UserTesting, Inc.
Andy Dear
978-609-1472
adear@usertesting.com

Startup Grind Scotland
Anna Brow, Head of Comms & PR
07546356846
hello@startupgrindscot.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye